Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance

RICHMOND, Va., May 23, 2024 /PRNewswire/ -- Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, announced that in anticipation of the expected primary listing of the Company's shares on Nasdaq , members of Indivior's senior leadership team will be hosting an analyst teach-in event today in New York City. The event, which will be webcast (see details below), is intended to provide an in-depth overview of Indivior's growth and value creation path. During the event, the Company will reconfirm its unchanged FY 2024 guidance as set forth below.

FY 2024

Net Revenue (NR)¹

$1,240m to $1,330m

 (+18% at midpoint vs. FY 2023)

SUBLOCADE NR

$820m to $880m

 (+35% at midpoint vs. FY 2023)

OPVEE NR

$15m to $25m¹

PERSERIS NR

$55m to $65m

 (+43% at midpoint vs. FY 2023)

SUBOXONE Film Market Share

Assumes historic rate of share decline in FY 2024 of 1
to 2 percentage points and the potential impact from
a fourth buprenorphine/naloxone sublingual film
generic in the U.S. market

Adjusted Gross Margin

Low to mid-80s range

Adjusted SG&A

($575m) to ($590m)

R&D

($120m) to ($130m)

Adjusted Operating Profit

$330m to $380m

1. The OPVEE NR guidance for FY 2024 includes approximately $8m as part of a multi-year agreement with the U.S. Biomedical Advancement Research and Development Authority (BARDA).